Program Schedule

94
Resistance to Last Resource Antibiotics: Mechanisms and Clinical Implications

Friday, October 10, 2014: 10:30 AM-12:00 PM
Room: The Pennsylvania Convention Center: 118-ABC

Learning Objectives:

This session is dedicated in memory to our esteemed colleague Dr. Robert C. Moellering, Jr. (1936-2014). Dr. Moellering was a former IDSA President, Maxwell Finland Named Lecturer and winner of the Alexander Fleming Award – IDSA’s highest achievement award.

At the conclusion of this session, participants will be able to:

  • identify emerging mechanisms of antibiotic resistance in S. aureus and their clinical implications
  • discuss changes in the population genetics of S. aureus and their impact on therapy
  • discuss  the molecular aspects related to the emergence of daptomycin resistance in vancomycin-resistant enterococci and their influence on breakpoint interpretation and therapeutic approaches
  • summarize the major determinants and mechanisms of carbapenem and colistin resistance and integrate this information into the decision making process for the treatment of multidrug-resistant Gram-negative bacteria

Target Audience: Scientists, Researchers, Pharmacists, Members-in-training, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Fellows, Clinicians, Academicians

Tracks: Investigative ID, Adult ID

Moderators:  Cesar Arias, MD PhD, University of Texas Medical School At Houston and Robert Bonomo, MD, Louis Stokes Cleveland Veterans Affairs Medical Center

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-122-L01-P

Disclosures:

C. Arias, Cubist Pharmaceuticals: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium
Forest Pharmaceuticals: Speaker's Bureau, Speaker honorarium
Pfizer: Grant Investigator and Speaker's Bureau, Research support and Speaker honorarium
Astra-Zeneca: Speaker's Bureau, Speaker honorarium
Novartis, Inc: Speaker's Bureau, Speaker honorarium
Bayer, Inc: Consultant, Consulting fee

R. Bonomo, None

P. Planet, Pfizer: Consultant, Consulting fee

C. Arias, Cubist Pharmaceuticals: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium
Forest Pharmaceuticals: Speaker's Bureau, Speaker honorarium
Pfizer: Grant Investigator and Speaker's Bureau, Research support and Speaker honorarium
Astra-Zeneca: Speaker's Bureau, Speaker honorarium
Novartis, Inc: Speaker's Bureau, Speaker honorarium
Bayer, Inc: Consultant, Consulting fee

R. Bonomo, AstraZeneca: Grant Investigator, Grant recipient
Merck: Grant Investigator, Grant recipient
Rib-X: Grant Investigator, Grant recipient
Steris: Grant Investigator, Grant recipient
TetraPhase: Scientific Advisor, nothing
NIH: Grant Investigator, Grant recipient
VA Merit Review: Grant Investigator, Grant recipient

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek